Akebia Therapeutics, Inc. (AKBA) AI Stock Analysis

Akebia Therapeutics, Inc. is a Cambridge, Massachusetts-based biopharmaceutical firm specializing in developing and commercializing therapies for kidney disease patients. Its primary clinical focus is vadadustat, an oral investigational therapy in Phase III development designed to treat anemia related to chronic kidney disease (CKD) in adult patients, whether dialysis-dependent or non-dialysis dependent. Akebia also markets Auryxia, a ferric citrate drug indicated to control serum phosphorus levels in dialysis-dependent adult CKD patients and to treat iron deficiency anemia in non-dialysis adult CKD patients. The company advances its pipeline through strategic international collaborations with Otsuka Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, and Janssen Pharmaceutica NV.

Akebia's financial performance has shown notable volatility across fiscal years. After revenue declined 17.7% to $160.2M in FY2024, FY2025 revenue rebounded 47.5% to $236.2M, driven by an 83.3% gross margin and an operating margin of 9.9%. FY2025 net income stood at -$5.3M with an EPS of -$0.00. However, the five-year revenue CAGR through FY2025 remained negative at -4.4%. For the trailing twelve months ended June 30, 2026, revenue was $219.1M, with an operating margin of -5.5% and a net profit margin of -13.5%. In the latest quarter ended June 30, 2026, quarterly revenue fell 21.4% year-over-year.

As of June 30, 2026, Akebia held $155.5M in cash and short-term investments alongside total debt of $54.0M, resulting in a net cash position of $101.6M. The company's current ratio was 1.43, and debt-to-equity stood at 2.16 on shareholders' equity of $25.0M. In FY2025, operating cash flow turned positive at $68.0M, matching free cash flow of $68.0M after minimal capital expenditures of $291,000. Over the five-year period through FY2025, the company's share count increased by 53.5%.

At a share price of $0.67 on October 16, 2026, Akebia carries a market capitalization of $185.7M and an enterprise value of $157.9M. Its forward P/E of 28.7x trades at a premium to the 17.3x forward P/E median of its US-listed Healthcare peers, while its EV/EBITDA of 64.4x exceeds the peer median of 12.0x. Conversely, its price-to-sales multiple of 0.8x is below the peer median of 4.1x. Over the past year, the stock dropped 77.1%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock fell 76.5%, underperforming the index's 83.0% gain.

Akebia holds 4 Strong Buy, 1 Buy, and 1 Hold rating from analysts, with no Sell or Strong Sell recommendations. The mean price target is $3.92, representing an upside of 484.6% from the October 16, 2026 closing price of $0.67. For FY2026, consensus estimates project an EPS of -$0.16 on revenue of $197.8M. For FY2027, two analysts project revenue to decrease 33.0% to $132.5M, with an EPS of -$0.36. The company has beaten EPS expectations in 2 of the past 4 quarters, with the next earnings release scheduled for November 9, 2026.

This page is an AI-written research summary of Akebia Therapeutics, Inc. (AKBA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AKBA income statement, AKBA balance sheet, AKBA key metrics, AKBA analyst forecast, AKBA chart. See the AKBA stock overview for the latest quote and news.